AutoZone price target raised to $1375 from $1300 at Wells Fargo

Technical Analysis

Volume is average for…

ShowHide Related Items >>

$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Initiation

Catch up on today’s…

Catch up on today’s top five analyst initiations with this list compiled by The Fly: 1. Arconic (ARNC) initiated with a Buy at Deutsche Bank. 2. Caesars (CZR) initiated with a Neutral at Goldman Sachs. 3. Overstock.com (OSTK) initiated with a Buy at Needham. 4. Inhibrx (INBX) initiated with a Buy at Jefferies as well as an Outperform at Evercore ISI and Credit Suisse. 5. Generac (GNRC) initiated with a Buy at Argus. This list is just a portion of The Fly’s analyst coverage. To see The Fly’s full Street Research coverage, click here.

ShowHide Related Items >>

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

GNRC Generac
$181.63 /

+3.02 (+1.69%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

09/13/20 Deutsche Bank
Arconic initiated with a Buy at Deutsche Bank
09/09/20 Benchmark
Arconic assumed with a Buy at Benchmark
05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
CZR Caesars
$52.53 /

+2.4 (+4.79%)

04:50 Today Goldman Sachs
Caesars initiated with a Neutral at Goldman Sachs
09/09/20 JPMorgan
Caesars price target raised to $55 from $50 at JPMorgan
08/13/20 JPMorgan
Caesars resumed with an Overweight at JPMorgan
08/03/20 Deutsche Bank
William Hill upgraded to Buy from Hold at Deutsche Bank
OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

05:40 Today Needham
Overstock.com initiated with a Buy at Needham
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
INBX Inhibrx
$18.22 /

+0.99 (+5.75%)

08:00 Today Jefferies
Inhibrx initiated with a Buy at Jefferies
06:14 Today Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
05:50 Today Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
GNRC Generac
$181.63 /

+3.02 (+1.69%)

07:35 Today Argus
Generac initiated with a Buy at Argus
09/03/20 Roth Capital
Generac price target raised to $210 from $190 at Roth Capital
08/21/20 Baird
Generac price target raised to $202 from $165 at Baird
08/13/20 Canaccord
Generac demand levels likely to capacity, says Canaccord
ARNC Arconic
$20.56 /

+1.45 (+7.59%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

GNRC Generac
$181.63 /

+3.02 (+1.69%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

INBX Inhibrx
$18.22 /

+0.99 (+5.75%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

Downgrade

Catch up on today’s…

Catch up on today’s top five analyst downgrades with this list compiled by The Fly: 1. Jazz Pharmaceuticals (JAZZ) downgraded to Sell from Neutral at Goldman Sachs with analyst Graig Suvannavejh saying he sees the company’s growth outlook as “challenged” and 6% downside risk in the shares. 2. Macerich (MAC) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Richard Hill saying he is shifting to an analysis of free cash flow as a better representation of the financial health of a company in the current environment of “rent deferral-driven deviations” in funds from operations for retail REITs. 3. Kroger (KR) downgraded to Neutral from Buy at BofA with analyst Robert Ohmes saying he has a more muted outlook for the company for the second half of FY21 and FY22 even though its multiple has been pushed out to 14-times expected earnings vs. 11-times average over the past two years. 4. Kala Pharmaceuticals (KALA) downgraded to Hold from Buy at Jefferies with analyst Biren Amin saying while he expects FDA approval for Eysuvis by its October 30 PDUFA date, the eye care professionals surveyed estimated Eysuvis could capture 12% market share at launch in year one and 13% in year two, assuming a price of $280/bottle. 5. MGM Resorts (MGM) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Grambling saying a slower recovery in Las Vegas will drive downside to consensus estimates and fundamental underperformance relative to peers. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, click here.

ShowHide Related Items >>

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

06:38 Today RBC Capital
Jazz Pharmaceuticals price target raised to $170 from $160 at RBC Capital
06:00 Today JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05:05 Today Goldman Sachs
Jazz Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
MAC Macerich
$7.05 /

-0.3 (-4.08%)

07:16 Today Morgan Stanley
Macerich downgraded to Underweight on downside risk at Morgan Stanley
05:34 Today Morgan Stanley
Macerich downgraded to Underweight from Equal Weight at Morgan Stanley
07/27/20 Deutsche Bank
Macerich price target lowered to $8 from $16 at Deutsche Bank
07/02/20 Citi
Macerich price target raised to $8 from $5 at Citi
KR Kroger
$33.17 /

-1.19 (-3.46%)

06:16 Today BofA
Kroger downgraded to Neutral from Buy at BofA
06:04 Today BofA
Kroger downgraded to Neutral from Buy at BofA
08/06/20 Credit Suisse
Kroger assumed with a Neutral at Credit Suisse
07/30/20 MKM Partners
Kroger initiated with a Neutral at MKM Partners
KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

06:54 Today Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
04:46 Today Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
07/23/20
Fly Intel: Top five analyst initiations
MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

04:54 Today Goldman Sachs
MGM Resorts downgraded to Sell from Neutral at Goldman Sachs
09/09/20 JPMorgan
MGM Resorts price target raised to $23 from $17 at JPMorgan
08/19/20 Credit Suisse
IAC price target raised to $160 from $91.68 at Credit Suisse
08/18/20 BMO Capital
IAC price target raised to $174 from $171 at BMO Capital
JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

Upgrade

Catch up on today’s…

Catch up on today’s top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Buy from Neutral at Goldman Sachs with Toshiya Hari saying ongoing weakness in DRAM and NAND pricing will be “short-lived” and Micron is well positioned competitively as it continues to execute on its technology transitions. 2. GameStop (GME) was upgraded to Outperform from Market Perform at Telsey Advisory and to Buy from Hold at Jefferies. 3. WWE (WWE) upgraded to Hold from Sell at Loop Capital with analyst Alan Gould saying that ratings continue to be challenging for the company and expenses are increasing relative to Q2, but he is raising his FY21 EPS view by 20c to $1.70 to reflect the more moderate growth rate in media costs and see no negative catalysts for WWE in the near term. 4. Vir Biotechnology (VIR) upgraded to Buy from Neutral at Goldman Sachs with analyst Paul Choi saying the company has identified two candidates from its antibody screening program, VIR-7831 and VIR-7832, for clinical development as both treatment for and prophylaxis against COVID-19. 5. Cirrus Logic (CRUS) upgraded to Equal Weight from Underweight at Barclays with analyst Blayne Curtis saying the stock is down over 20% since earnings while December quarter estimates are achievable. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, click here.

ShowHide Related Items >>

MU Micron
$49.09 /

+3 (+6.51%)

GME GameStop
$6.58 /

+0.49 (+8.05%)

WWE WWE
$41.00 /

-0.15 (-0.36%)

VIR Vir Biotechnology
$32.41 /

+3.98 (+14.00%)

MU Micron
$49.09 /

+3 (+6.51%)

05:21 Today Goldman Sachs
Micron upgraded to Buy from Neutral at Goldman Sachs
08/27/20 Citi
Citi cuts Micron estimates on latest Huawei ban, reiterates Sell rating
08/20/20 Cleveland Research
Micron shares have downside on DRAM price declines, says Cleveland Research
08/18/20 Mizuho
Micron price target lowered to $58 from $63 at Mizuho
GME GameStop
$6.58 /

+0.49 (+8.05%)

06:46 Today Jefferies
GameStop upgraded to Buy ahead of video game console cycle at Jefferies
05:13 Today Telsey Advisory
GameStop upgraded to Outperform from Market Perform at Telsey Advisory
04:47 Today Jefferies
GameStop upgraded to Buy from Hold at Jefferies
09/10/20 Baird
GameStop can still hit breakeven EBITDA this year, says Baird
WWE WWE
$41.00 /

-0.15 (-0.36%)

07:22 Today Loop Capital
WWE upgraded to Hold from Sell at Loop Capital
05:13 Today Loop Capital
WWE upgraded to Hold from Sell at Loop Capital
07/31/20 Guggenheim
WWE price target raised to $66 from $60 at Guggenheim
07/10/20 Loop Capital
WWE price target raised to $37 from $30 at Loop Capital
VIR Vir Biotechnology
$32.41 /

+3.98 (+14.00%)

04:57 Today Goldman Sachs
Vir Biotechnology upgraded to Buy from Neutral at Goldman Sachs
09/11/20 JPMorgan
Vir Biotechnology upgraded to Neutral ahead of catalysts at JPMorgan
09/11/20 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
08/31/20 Goldman Sachs
Vir Biotechnology price target raised to $48 from $43 at Goldman Sachs
CRUS Cirrus Logic
$59.63 /

+1.64 (+2.83%)

06:47 Today Barclays
Barclays upgrades Cirrus Logic to Equal Weight ahead of Apple 5G cycle
05:34 Today Barclays
Cirrus Logic upgraded to Equal Weight from Underweight at Barclays
09/10/20 Craig-Hallum
Cirrus Logic upgraded to Buy at Craig-Hallum following recent share selloff
09/10/20 Craig-Hallum
Cirrus Logic upgraded to Buy from Hold at Craig-Hallum
MU Micron
$49.09 /

+3 (+6.51%)

GME GameStop
$6.58 /

+0.49 (+8.05%)

WWE WWE
$41.00 /

-0.15 (-0.36%)

VIR Vir Biotechnology
$32.41 /

+3.98 (+14.00%)

CRUS Cirrus Logic
$59.63 /

+1.64 (+2.83%)

MU Micron
$49.09 /

+3 (+6.51%)

GME GameStop
$6.58 /

+0.49 (+8.05%)

WWE WWE
$41.00 /

-0.15 (-0.36%)

VIR Vir Biotechnology
$32.41 /

+3.98 (+14.00%)

MU Micron
$49.09 /

+3 (+6.51%)

GME GameStop
$6.58 /

+0.49 (+8.05%)

WWE WWE
$41.00 /

-0.15 (-0.36%)

VIR Vir Biotechnology
$32.41 /

+3.98 (+14.00%)

CRUS Cirrus Logic
$59.63 /

+1.64 (+2.83%)

MU Micron
$49.09 /

+3 (+6.51%)

GME GameStop
$6.58 /

+0.49 (+8.05%)

WWE WWE
$41.00 /

-0.15 (-0.36%)

Options

Bearish flow noted in…

ShowHide Related Items >>

CVNA Carvana
$172.20 /

-1.9 (-1.09%)

CVNA Carvana
$172.20 /

-1.9 (-1.09%)

08/12/20
Fly Intel: Top five analyst initiations
08/11/20 Stifel
Carvana initiated with a Hold at Stifel
08/11/20 Citi
Carvana price target raised to $240 from $120 at Citi
08/10/20 Oppenheimer
Carvana price target raised to $250 from $127 at Oppenheimer
CVNA Carvana
$172.20 /

-1.9 (-1.09%)

CVNA Carvana
$172.20 /

-1.9 (-1.09%)

CVNA Carvana
$172.20 /

-1.9 (-1.09%)

CVNA Carvana
$172.20 /

-1.9 (-1.09%)

Latest posts